Futura Medical to Host R&D Day in February 2019
17 December 2018
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces plans to host an R&D Day in London for analysts and institutional investors on Monday 11 February 2019.
The event will feature a presentation from a Key Opinion Leader in erectile dysfunction ("ED") and will provide an opportunity to hear about the Company, its R&D strategy with a focus on its DermaSys® drug delivery technology and lead product MED2005, a topical glyceryl trinitrate ("GTN") gel for the treatment of ED.
James Barder, Chief Executive Officer of Futura Medical, said: "We are looking forward to hosting the event which will build on our initial Advisory Panel meeting hosted by Futura at the 19th Annual Fall Scientific Meeting of Sexual Medicines Society of North America in November 2018, and was extremely well received and productive. The Advisory Panel were unanimous in their view that there has been little recent credible innovation in the treatment of ED. They were therefore excited by the meaningful PK and Phase 2 findings presented on our lead programme MED2005, demonstrating the potential of MED2005 as both a topical and fast-acting erectile dysfunction treatment, key differentiators to other ED products on the market. There was also a unanimous desire by the panel to remain involved with the development programme for MED2005 and the panel look forward to reviewing the results from our ongoing Phase 3 trial when published in Q4 2019."
Dr. Wayne J.G. Hellstrom is Professor of Urology and Chief of Andrology at Tulane University School of Medicine in New Orleans and member of the Futura Medical Advisory Panel, said: "The treatment of ED has not seen any new clinical products for nearly two decades. MED2005 is a novel glyceryl trinitrate (GTN) topical gel with an enhanced absorption delivery system. After application to the glans penis, there is a rapid onset of action (5-10 mins in 70% of spontaneous attempts at intercourse) in contrast to current oral PDE5i's, which can take 30-90 mins to act. This novel topical therapy is easy to use, does not have any food or alcohol interactions, and has excellent tolerability for both patient and partner.
"I am excited to be part of an advisory panel helping to shape the future programme for MED2005 as it enters Phase 3 studies, and I look forward to ultimate approval by the FDA and regulators around the world. It offers new hope to patients who, for whatever reason, are dissatisfied with current therapies or are precluded from their use."
In October 2018, Futura announced that the first patient had been enrolled in the first Phase 3 study, ("FM57") of MED2005 that will recruit approximately 1,000 patients with mild, moderate or severe ED across nine countries in Central and Eastern Europe. The Phase 3 study remains on track, with headline data expected by the end of 2019.
For further information on the R&D day, or to register your interest, please contact Optimum Strategic Communications at [email protected]. Further information will be made available in January 2019.
The event will be webcast and will be made available on the investor section of website shortly after the event.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: [email protected]
Tel: +44 (0) 1483 685 670
Nominated Adviser and Broker:
N+1 Singer
Aubrey Powell/ Ben Farrow (Corporate Finance)
Mia Gardner / Tom Salvesen (Corporate Broking)
Tel: +44 (0) 20 7496 3000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: [email protected]
Tel: +44 (0) 203 950 9144
Notes to editors
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
Dr. Wayne J.G. Hellstrom
Dr. Wayne J.G. Hellstrom is Professor of Urology and Chief of Andrology (male infertility and sexual dysfunction) at Tulane University School of Medicine in New Orleans, where he has been since 1988. His practice is specialized in the diagnosis and treatment of sexual dysfunction including Peyronie's disease, surgical and vascular reconstruction, prosthetic surgery, male infertility (both surgical and medical therapies), BPH, and urethral stricture disease.
A clinician, author, and lecturer, Hellstrom has published numerous peer-reviewed articles in professional publications and has contributed numerous chapters in textbooks. He also is the editor of "Male Infertility and Sexual Dysfunction" and "The Handbook of Sexual Dysfunction."
Dr. Hellstrom earned his undergraduate and medical degrees at McGill University in Montreal, completed his urology residency at the University of California at San Francisco, and his fellowship at the University of California at Davis. He has been awarded many honours in the field of urology, male infertility, and erectile dysfunction.
